紅星發展(600367.SH)擬延長非公開發行股票股東大會決議及授權的有效期
格隆匯1月3日丨紅星發展(600367.SH)公佈,鑑於此次非公開發行股票的股東大會決議有效期即將到期,為確保公司此次非公開發行股票的順利進行,公司於2020年1月3日召開的第七屆董事會第十七次會議審議通過了《關於延長公司非公開發行A股股票股東大會決議有效期》和《關於提請股東大會延長授權董事會全權辦理非公開發行相關事宜有效期》的議案,公司擬延長此次非公開發行股票股東大會決議及授權的有效期為自前次決議有效期屆滿之日起12個月,即有效期自2020年1月23日至2021年1月22日。除延長有效期外,此次非公開發行股票方案的其它內容不變。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.